272 related articles for article (PubMed ID: 31722061)
1. A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer.
Franceschini D; Cozzi L; De Rose F; Navarria P; Fogliata A; Franzese C; Pezzulla D; Tomatis S; Reggiori G; Scorsetti M
Strahlenther Onkol; 2020 Oct; 196(10):922-931. PubMed ID: 31722061
[TBL] [Abstract][Full Text] [Related]
2. A PET/CT radiomics model for predicting distant metastasis in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy: a multicentric study.
Yu L; Zhang Z; Yi H; Wang J; Li J; Wang X; Bai H; Ge H; Zheng X; Ni J; Qi H; Guan Y; Xu W; Zhu Z; Xing L; Dekker A; Wee L; Traverso A; Ye Z; Yuan Z
Radiat Oncol; 2024 Jan; 19(1):10. PubMed ID: 38254106
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment
Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
[TBL] [Abstract][Full Text] [Related]
4. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
[TBL] [Abstract][Full Text] [Related]
5. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.
Kirienko M; Cozzi L; Antunovic L; Lozza L; Fogliata A; Voulaz E; Rossi A; Chiti A; Sollini M
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):207-217. PubMed ID: 28944403
[TBL] [Abstract][Full Text] [Related]
6. Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients.
Qin Q; Shi A; Zhang R; Wen Q; Niu T; Chen J; Qiu Q; Wan Y; Sun X; Xing L
Thorac Cancer; 2020 Apr; 11(4):964-972. PubMed ID: 32061061
[TBL] [Abstract][Full Text] [Related]
7. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation.
Thor M; Fitzgerald K; Apte A; Oh JH; Iyer A; Odiase O; Nadeem S; Yorke ED; Chaft J; Wu AJ; Offin M; Simone Ii CB; Preeshagul I; Gelblum DY; Gomez D; Deasy JO; Rimner A
Radiother Oncol; 2024 Jan; 190():109983. PubMed ID: 37926331
[TBL] [Abstract][Full Text] [Related]
8. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.
Mattonen SA; Palma DA; Johnson C; Louie AV; Landis M; Rodrigues G; Chan I; Etemad-Rezai R; Yeung TP; Senan S; Ward AD
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1121-8. PubMed ID: 26907916
[TBL] [Abstract][Full Text] [Related]
9. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
[TBL] [Abstract][Full Text] [Related]
10. Deep segmentation networks predict survival of non-small cell lung cancer.
Baek S; He Y; Allen BG; Buatti JM; Smith BJ; Tong L; Sun Z; Wu J; Diehn M; Loo BW; Plichta KA; Seyedin SN; Gannon M; Cabel KR; Kim Y; Wu X
Sci Rep; 2019 Nov; 9(1):17286. PubMed ID: 31754135
[TBL] [Abstract][Full Text] [Related]
11. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
12. CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer.
Huynh E; Coroller TP; Narayan V; Agrawal V; Hou Y; Romano J; Franco I; Mak RH; Aerts HJ
Radiother Oncol; 2016 Aug; 120(2):258-66. PubMed ID: 27296412
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a venous computed tomography radiomics model to predict lymph node metastasis from non-small cell lung cancer.
Cong M; Yao H; Liu H; Huang L; Shi G
Medicine (Baltimore); 2020 May; 99(18):e20074. PubMed ID: 32358390
[TBL] [Abstract][Full Text] [Related]
14. Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.
Jiao Z; Li H; Xiao Y; Aggarwal C; Galperin-Aizenberg M; Pryma D; Simone CB; Feigenberg SJ; Kao GD; Fan Y
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1647-1656. PubMed ID: 33333202
[TBL] [Abstract][Full Text] [Related]
15. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
[TBL] [Abstract][Full Text] [Related]
16. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
[TBL] [Abstract][Full Text] [Related]
17. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of mediastinal metastatic lymph nodes in NSCLC based on radiomic features in different phases of CT imaging.
Sha X; Gong G; Qiu Q; Duan J; Li D; Yin Y
BMC Med Imaging; 2020 Feb; 20(1):12. PubMed ID: 32024469
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer.
Yu W; Tang C; Hobbs BP; Li X; Koay EJ; Wistuba II; Sepesi B; Behrens C; Rodriguez Canales J; Parra Cuentas ER; Erasmus JJ; Court LE; Chang JY
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1090-1097. PubMed ID: 29246722
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pathological nodal involvement by CT-based Radiomic features of the primary tumor in patients with clinically node-negative peripheral lung adenocarcinomas.
Liu Y; Kim J; Balagurunathan Y; Hawkins S; Stringfield O; Schabath MB; Li Q; Qu F; Liu S; Garcia AL; Ye Z; Gillies RJ
Med Phys; 2018 Jun; 45(6):2518-2526. PubMed ID: 29624702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
